Share on StockTwits

Analysts at Raymond James upped their target price on shares of OraSure Technologies (NASDAQ:OSUR) from $8.50 to $9.00 in a research report issued to clients and investors on Thursday. Raymond James’ price target points to a potential upside of 20.32% from the stock’s previous close.

OraSure Technologies (NASDAQ:OSUR) traded up 0.13% on Thursday, hitting $7.49. 495,222 shares of the company’s stock traded hands. OraSure Technologies has a 52-week low of $3.75 and a 52-week high of $8.60. The stock has a 50-day moving average of $6.45 and a 200-day moving average of $6.66. The company’s market cap is $418.2 million.

OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.03. The company had revenue of $23.50 million for the quarter, compared to the consensus estimate of $23.28 million. During the same quarter in the previous year, the company posted ($0.18) earnings per share. The company’s revenue for the quarter was up 10.8% on a year-over-year basis. On average, analysts predict that OraSure Technologies will post $-0.23 earnings per share for the current fiscal year.

A number of other firms have also recently commented on OSUR. Analysts at Canaccord Genuity raised their price target on shares of OraSure Technologies from $10.00 to $11.00 in a research note on Thursday. They now have a “buy” rating on the stock. Separately, analysts at Mizuho raised their price target on shares of OraSure Technologies from $9.00 to $10.00 in a research note on Wednesday. They now have a “buy” rating on the stock. Finally, analysts at TheStreet downgraded shares of OraSure Technologies from a “hold” rating to a “sell” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $8.93.

OraSure Technologies, Inc, is engaged in development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using the Company’s oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.